- Home
- PAVM vs SILO Comparison
PAVM vs SILO Comparison
Compare PAVM & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- SILO
- Stock Information
- Founded
- PAVM 2014
- SILO 2010
- Country
- PAVM United States
- SILO United States
- Employees
- PAVM N/A
- SILO N/A
- Industry
- PAVM Medical/Dental Instruments
- SILO Apparel
- Sector
- PAVM Health Care
- SILO Consumer Discretionary
- Exchange
- PAVM Nasdaq
- SILO Nasdaq
- Market Cap
- PAVM 9.4M
- SILO 8.0M
- IPO Year
- PAVM 2016
- SILO N/A
- Fundamental
- Price
- PAVM $0.43
- SILO $0.55
- Analyst Decision
- PAVM Strong Buy
- SILO
- Analyst Count
- PAVM 1
- SILO 0
- Target Price
- PAVM $20.00
- SILO N/A
- AVG Volume (30 Days)
- PAVM 738.1K
- SILO 813.6K
- Earning Date
- PAVM 11-12-2025
- SILO 11-12-2025
- Dividend Yield
- PAVM N/A
- SILO N/A
- EPS Growth
- PAVM N/A
- SILO N/A
- EPS
- PAVM 0.83
- SILO N/A
- Revenue
- PAVM $1,020,000.00
- SILO $72,102.00
- Revenue This Year
- PAVM N/A
- SILO $1.86
- Revenue Next Year
- PAVM $234.47
- SILO N/A
- P/E Ratio
- PAVM $0.52
- SILO N/A
- Revenue Growth
- PAVM N/A
- SILO N/A
- 52 Week Low
- PAVM $0.30
- SILO $0.40
- 52 Week High
- PAVM $1.25
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- PAVM 44.31
- SILO 40.03
- Support Level
- PAVM $0.40
- SILO $0.53
- Resistance Level
- PAVM $0.48
- SILO $0.62
- Average True Range (ATR)
- PAVM 0.06
- SILO 0.06
- MACD
- PAVM -0.01
- SILO -0.01
- Stochastic Oscillator
- PAVM 19.15
- SILO 50.83
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.